Study of Tocilizumab to Treat Polymyalgia Rheumatica
Information source: Hospital for Special Surgery, New York
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Polymyalgia Rheumatica (PMR)
Intervention: Tocilizumab (Drug)
Phase: Phase 2
Status: Active, not recruiting
Sponsored by: Hospital for Special Surgery, New York Official(s) and/or principal investigator(s): Robert F Spiera, MD, Principal Investigator, Affiliation: Hospital for Special Surgery, New York
Summary
This is a fifteen-month open label, Phase IIa clinical trial is being conducted to assess
the tolerability, safety and efficacy of a medication called Tocilizumab (Actemra®) in
patients with polymyalgia rheumatica (PMR).
Clinical Details
Official title: Phase IIa of Tocilizumab In the Treatment of Polymyalgia Rheumatica
Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Proportion of Patients in Disease Remission at Six Months from Trial EntryNumber of Participants with Adverse Events as a Measure of Safety and Tolerability
Secondary outcome: Proportion of patients able to achieve Disease Remission (DR) off corticosteroids, without Disease Relapse or RecurrenceProportion of patients who develop Disease Relapses The proportion of patients who develop Disease Recurrences The cumulative dose of prednisone
Detailed description:
This fifteen-month open label, Phase IIa clinical trial is being conducted to assess the
tolerability, safety and efficacy of a medication called Tocilizumab (Actemra®) in patients
with polymyalgia rheumatica (PMR). The typical symptoms of PMR are muscle pain and stiffness
in the shoulder, neck or hip region. Steroids have traditionally been used to treat this
condition with great success, although long courses of steroids, up to 2 years in many
cases, are often required. This can result in many unwanted side effects including diabetes,
high blood pressure, heart disease, cataracts, weak bones with fractures, weak muscles, skin
bruising, difficulty sleeping and mood disturbances. In this trial, the steroid dosage will
be decreased much more quickly than what is done in routine clinical practice; there is an
expectation that steroid therapy will be withdrawn within six months.
Tocilizumab is a medication already on the market that has been FDA approved in the US and
Japan for the treatment of rheumatoid arthritis, and in Japan it is also approved for
certain types of juvenile idiopathic arthritis (which is like rheumatoid arthritis in
children) and Castleman's disease (which is a rare disease that causes enlarged lymph
nodes). It is not FDA approved to treat polymyalgia rheumatica at this time. In this study,
it will be given as an intravenous infusion once a month for a treatment period of one year.
Experiments done on the blood of patients with PMR show one particular cytokine or small
molecule that circulates throughout the body, interleukin-6, to be elevated in this disease.
Tocilizumab is a medication that is designed to specifically block this cytokine. The
co-primary endpoints for this study include efficacy, as well as evaluations of safety and
tolerability.
- Efficacy will be defined by the proportion of patients in Disease Remission (DR) off
corticosteroids, without relapse or recurrence, at six months from trial entry
- Safety and tolerability of Tocilizumab will be evaluated during the fifteen-month study
period by the monitoring of adverse events and immunogenicity surveillance
Disease Remission (DR) will be defined as the disappearance of signs and symptoms of
polymyalgia rheumatica (aching and stiffness of the shoulder, hip girdle, or both) with
normalization of erythrocyte sedimentation rate (ESR<30 mm/hr) and c-reactive protein (CRP
≤1. 0 mg/dl), unless elevation of ESR and/or CRP are attributable to causes other than PMR
(i. e., infection).
Eligibility
Minimum age: 50 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Disease- Specific Inclusion Criteria:
Patients must meet the following inclusion criteria to be eligible for study entry:
Diagnosed with polymyalgia rheumatica and enrolled within one month of diagnosis.
Disease Specific Exclusion Criteria:
Patients will be excluded from the study based on the following criteria:
- Symptoms or diagnosis of temporal arteritis, including headache, jaw claudication,
hyperesthesia of scalp, abnormal palpated temporal artery, visual disturbances,
temporal artery biopsy positivity
- Concurrent rheumatoid arthritis
- Presence of rheumatoid factor and CCP
- Other inflammatory arthritis or other connective tissue diseases, such as but not
limited to systemic lupus erythematosus, systemic sclerosis, vasculitis,
polymyositis, dermatomyositis, mixed connective tissue disease
- Treatment of polymyalgia rheumatica with more than 20mg of daily prednisone or its
equivalent at the time of screening
- Treatment with more than 30mg of daily prednisone or its equivalent since diagnosis.
Treatment with 30mg of daily prednisone or its equivalent since diagnosis for more
than 2 weeks.
- More than 4 weeks of corticosteroid therapy prior to enrollment
- History of bowel perforation within the past five years.
- Active diverticulitis.
- Pre-existing or recent onset demyelinating disorders
Locations and Contacts
Hospital for Special Surgery, New York, New York 100214898, United States
Additional Information
Starting date: July 2011
Last updated: March 18, 2015
|